NAVCO Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

NAVCO Pharmaceuticals has a total shareholder equity of CA$19.9K and total debt of CA$693.6K, which brings its debt-to-equity ratio to 3488.3%. Its total assets and total liabilities are CA$951.3K and CA$931.4K respectively.

Key information

3,488.3%

Debt to equity ratio

CA$693.58k

Debt

Interest coverage ratio	n/a
Cash	CA$11.21k
Equity	CA$19.88k
Total liabilities	CA$931.44k
Total assets	CA$951.32k

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: F0U's short term assets (CA$134.8K) do not cover its short term liabilities (CA$850.9K).

Long Term Liabilities: F0U's short term assets (CA$134.8K) exceed its long term liabilities (CA$80.5K).

Debt to Equity History and Analysis

Debt Level: F0U's net debt to equity ratio (3431.9%) is considered high.

Reducing Debt: Insufficient data to determine if F0U's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: F0U's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if F0U's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 07:47
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NAVCO Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution